<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuznar, Wayne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Hankey, Graeme J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Stroke Prevention in Atrial Fibrillation: The Roles of Anticoagulants, Devices, and Antidotes</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">33-34</style></pages><abstract><style  face="normal" font="default" size="100%">This article reviews tools for risk stratification for stroke and bleeding among patients with atrial fibrillation (AF). The CHADS2 score is frequently used to estimate the risk of stroke in AF patients and to help determine the appropriateness of anticoagulant therapy. Also discussed are the benefit-risk of warfarin and the new oral anticoagulants (OACs), multiple clinical trials, as well as the measurement and monitoring of the anticoagulant effects of new OACs.</style></abstract><number><style face="normal" font="default" size="100%">20</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>